| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Silvio E Inzucchi | Q114335783 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 360-372 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Oral antihyperglycemic therapy for type 2 diabetes: scientific review | |
| P478 | volume | 287 |
| Q34161881 | A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor |
| Q79635974 | A [meso-tetrakis(4-sulfonatophenyl)porphyrinato]zinc(ii) complex as an oral therapeutic for the treatment of type 2 diabetic KKA(y) mice |
| Q46766527 | A crossover study on lipid and weight changes associated with olanzapine and risperidone |
| Q51501369 | A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. |
| Q45334953 | A molecular connection of Pterocarpus marsupium, Eugenia jambolana and Gymnema sylvestre with dipeptidyl peptidase-4 in the treatment of diabetes |
| Q37890777 | A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition |
| Q82428933 | A novel treatment strategy for type 2 diabetes: Targeting glucose variability and β-cell failure |
| Q51293354 | A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. |
| Q44197835 | A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial |
| Q34398616 | A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus |
| Q51371873 | A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve ty |
| Q36536205 | A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes |
| Q37750257 | A review of the response to oral antidiabetes agents in patients with type 2 diabetes |
| Q43252939 | A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus |
| Q42714656 | A study on the hypoglycemic and hypolipidemic effects of an ayurvedic drug Rajanyamalakadi in diabetic patients |
| Q36570720 | Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry |
| Q51363561 | Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. |
| Q36784264 | Addition of basal insulin to oral antidiabetic agents: a goal-directed approach to type 2 diabetes therapy. |
| Q46920661 | Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study |
| Q33603409 | Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks |
| Q90479839 | Addressing Stem Cell Therapeutic Approaches in Pathobiology of Diabetes and Its Complications |
| Q36241454 | Advances in epidemiology and treatment of type 2 diabetes in children |
| Q38072616 | Advances in pharmacologic therapies for type 2 diabetes |
| Q80985562 | Amelioration of hyperglycemia and metabolic syndromes in type 2 diabetic KKA(y) mice by poly(gamma-glutamic acid)oxovanadium(IV) complex |
| Q28828825 | Anti-Diabetic Effect of Portulaca oleracea L. Polysaccharideandits Mechanism in Diabetic Rats |
| Q99570859 | Anti-Diabetic Obesity Effects of Wasabia Japonica Matsum Leaf Extract on 45% Kcal High-Fat Diet-Fed Mice |
| Q49334257 | Anti-hyperglycemic effects and signaling mechanism of Perilla frutescens sprout extract |
| Q37001015 | Anti-obesity and anti-diabetic effects of a standardized potato extract in ob/ob mice |
| Q40486968 | Anti-obesity effects of yellow catfish protein hydrolysate on mice fed a 45% kcal high-fat diet |
| Q90419939 | Antidiabetic Potential of Medicinal Plants and Their Active Components |
| Q40851859 | Antidiabetic and Antilipidemic Effect of Musa balbisiana Root Extract: A Potent Agent for Glucose Homeostasis in Streptozotocin-Induced Diabetic Rat |
| Q47902465 | Antidiabetic plant-derived nutraceuticals: a critical review |
| Q37457547 | Antioxidant and antidiabetic activities of extracts from Cirsium japonicum roots |
| Q37549014 | Antioxidant and hepatoprotective effects of fermented red ginseng against high fat diet-induced hyperlipidemia in rats |
| Q92910500 | Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes |
| Q31122704 | Are hypoglycaemia and other adverse effects similar among sulphonylureas? |
| Q36640590 | Are sulfonylureas passé? |
| Q45115370 | Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study |
| Q64246806 | Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: Pooled analysis from 5 cohorts |
| Q49679474 | Bioanalytical methods for the detection of antidiabetic drugs: a review. |
| Q34146068 | Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers |
| Q92068307 | Biosynthesis of Silver Nanoparticles from Melia azedarach: Enhancement of Antibacterial, Wound Healing, Antidiabetic and Antioxidant Activities |
| Q37636162 | Biphasic insulin aspart in the treatment of type 2 diabetes mellitus |
| Q34717929 | Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus |
| Q58375443 | Cardiovascular disease prevention |
| Q36649277 | Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis |
| Q46758010 | Cardiovascular, metabolic and hormonal responses to the progressive exercise performed to exhaustion in patients with type 2 diabetes treated with metformin or glyburide |
| Q34299670 | Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). |
| Q36996546 | Clinical presentation and treatment of type 2 diabetes in children |
| Q35579452 | Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus |
| Q27026211 | Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination |
| Q34620565 | Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes |
| Q34438700 | Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor behind the Scene |
| Q36283803 | Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus |
| Q35887411 | Combined thiazolidinedione-insulin therapy: should we be concerned about safety? |
| Q37416127 | Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. |
| Q38677949 | Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity |
| Q35614295 | Common problems in outpatient management of patients with diabetes in the age of insulin analogues |
| Q57932324 | Comparative in vitro-in vivo correlation analysis with pioglitazone tablets |
| Q51359217 | Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. |
| Q46955559 | Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes |
| Q43045655 | Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes |
| Q38116766 | Complementing insulin therapy to achieve glycemic control |
| Q44804224 | Compliance and optimisation of oral antidiabetic therapy. A longitudinal study |
| Q35031636 | Compliance with national guidelines in patients with diabetes in a family practice clinic |
| Q42867343 | Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications |
| Q33323489 | Cost-efficient treatment for uninsured or underinsured patients with hypertension, depression, diabetes mellitus, insomnia, and gastroesophageal reflux |
| Q24651966 | Costus spicatus tea failed to improve diabetic progression in C57BLKS/J db/db mice, a model of type 2 diabetes mellitus |
| Q33723387 | Current therapeutic options in type 2 diabetes mellitus: a practical approach |
| Q36729115 | DPPIV inhibition: promising therapy for the treatment of type 2 diabetes |
| Q34153496 | Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial |
| Q37990891 | Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus |
| Q38018930 | Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes |
| Q42354624 | Design and In-vitro Evaluation of Sustained Release Floating Tablets of Metformin HCl Based on Effervescence and Swelling |
| Q51660225 | Design and optimization of a stomach-specific drug delivery system of repaglinide: Application of simplex lattice design |
| Q35279474 | Developing multi-faith chaplaincy. |
| Q92028596 | Development of a Novel Series of Anticancer and Antidiabetic: Spirothiazolidines Analogs |
| Q58696993 | Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds |
| Q36507637 | Diabetes and dyslipidaemia |
| Q28394087 | Diabetes in African Americans |
| Q38036772 | Diabetes pharmacotherapy in 2012: considerations in medication selection |
| Q37102832 | Diabetes prevention: can insulin secretagogues do the job? |
| Q33446693 | Diabetes: glycaemic control in type 2. |
| Q59220162 | Diabetic nephropathy |
| Q36892807 | Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus |
| Q36773485 | Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin |
| Q37848844 | Disposition of metformin: variability due to polymorphisms of organic cation transporters |
| Q34257350 | Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study |
| Q95817945 | Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update |
| Q35187795 | Drug therapy of diabetes in the elderly |
| Q85305515 | Early therapy for type 2 diabetes in China |
| Q44511825 | Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. |
| Q51478119 | Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. |
| Q41350580 | Effect of combined therapy of diabinese and nicotinic acid on liver enzymes in rabbits with dithizone-induced diabetes |
| Q34313718 | Effect of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials. |
| Q36350528 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance |
| Q51382786 | Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. |
| Q33467412 | Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes |
| Q47281545 | Effect of oral supplementation of composite leaf extract of medicinal plants on biomarkers of oxidative stress in induced diabetic Wistar rats |
| Q54593088 | Effect of oryzanol and ferulic acid on the glucose metabolism of mice fed with a high-fat diet. |
| Q40541424 | Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses? |
| Q28743191 | Effect of switching to a high-deductible health plan on use of chronic medications |
| Q80404029 | Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats |
| Q37240102 | Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes |
| Q37672754 | Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study |
| Q35797022 | Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. |
| Q36758200 | Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation |
| Q35382193 | Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis |
| Q45218168 | Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients |
| Q33585792 | Efficacy and safety of ginsam, a vinegar extract from Panax ginseng, in type 2 diabetic patients: Results of a double-blind, placebo-controlled study. |
| Q37394223 | Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial |
| Q45545993 | Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes |
| Q35159576 | Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis |
| Q36782645 | Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency |
| Q51346295 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. |
| Q41964667 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, |
| Q51478110 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. |
| Q35228228 | Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus |
| Q34595451 | Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome in patients with secondary sulfonylurea failure: A comparative study |
| Q38445269 | Emerging treatments for post-transplantation diabetes mellitus |
| Q50781900 | Enhanced oral bioavailability and sustained delivery of glimepiride via niosomal encapsulation: in-vitro characterization and in-vivo evaluation. |
| Q42140963 | Enzyme inhibitory and radical scavenging effects of some antidiabetic plants of Turkey |
| Q48291217 | Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study |
| Q46082607 | Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet |
| Q35098802 | Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents. |
| Q46517474 | Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis |
| Q41883800 | FGT-1 is the major glucose transporter in C. elegans and is central to aging pathways |
| Q28475588 | Factors associated with results and conclusions of trials of thiazolidinediones |
| Q34475066 | Fast and environmentally friendly quantitative analysis of active agents in anti-diabetic tablets by an alternative laser-induced breakdown spectroscopy (LIBS) method and comparison to a validated reversed-phase high-performance liquid chromatograph |
| Q36329786 | Fermentation of Green Tea with 2% Aquilariae lignum Increases the Anti-Diabetic Activity of Green Tea Aqueous Extracts in the High Fat-Fed Mouse |
| Q46425986 | Formulation, physicochemical characterization and in-vivo evaluation of ion-sensitive metformin loaded-biopolymeric beads |
| Q35661969 | Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study |
| Q41762575 | Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG. |
| Q44896352 | Future targets in the treatment of type 2 diabetes |
| Q34837085 | Genetically defined pancreatic beta cell failure |
| Q28261829 | Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose |
| Q38244345 | Glioma stem cells: markers, hallmarks and therapeutic targeting by metformin |
| Q44764298 | Glycemic index in the treatment of diabetes: the debate continues |
| Q36404965 | Glycemic response to newly initiated diabetes therapies |
| Q37284447 | Gynura procumbens extract improves insulin sensitivity and suppresses hepatic gluconeogenesis in C57BL/KsJ-db/db mice |
| Q46504420 | Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study |
| Q48274537 | Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment |
| Q46023795 | Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. |
| Q51299330 | Hypoglycemic effects of Zanthoxylum alkylamides by enhancing glucose metabolism and ameliorating pancreatic dysfunction in streptozotocin-induced diabetic rats. |
| Q50745656 | Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus. |
| Q24670563 | Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination |
| Q36907473 | Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study |
| Q37071750 | Impact of therapeutic advances on hypoglycaemia in type 2 diabetes |
| Q38114507 | Importance of dairy products in cardiovascular diseases and type 2 diabetes. |
| Q41832683 | In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy |
| Q37592079 | In-vitro Studies on Calotropis procera Leaf Extracts as Inhibitors of Key Enzymes Linked to Diabetes Mellitus |
| Q37280699 | Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes |
| Q38069507 | Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction |
| Q42578569 | Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus |
| Q83470443 | Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin |
| Q36856384 | Inhaled human [rDNA origin] insulin, a novel formulation for diabetes mellitus |
| Q36580608 | Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes |
| Q42359993 | Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus |
| Q51365744 | Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. |
| Q51488169 | Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. |
| Q87984385 | Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics simulations |
| Q36978835 | Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes |
| Q38234927 | Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia |
| Q34962291 | Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions |
| Q35219417 | Insulin therapy for type 2 diabetes |
| Q38883620 | Insulin, insulin receptors, and cancer. |
| Q36349625 | Is exenatide advancing the treatment of type 2 diabetes? |
| Q37845218 | Is the GLP-1 system a viable therapeutic target for weight reduction? |
| Q37443837 | Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes |
| Q24538695 | Kir6.2 is required for adaptation to stress |
| Q38062881 | Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology |
| Q47333601 | Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus |
| Q46606075 | Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus |
| Q43470326 | Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. |
| Q93165383 | Low-Dose Decitabine Assists Human Umbilical Cord-Derived Mesenchymal Stem Cells in Protecting β Cells via the Modulation of the Macrophage Phenotype in Type 2 Diabetic Mice |
| Q35212563 | Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease |
| Q36090624 | Management of diabetes mellitus medications in the nursing home |
| Q36519973 | Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. |
| Q34620649 | Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy |
| Q36523427 | Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies |
| Q34862358 | Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes |
| Q24642503 | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes |
| Q36309632 | Medications associated with weight gain |
| Q24245352 | Meglitinide analogues for type 2 diabetes mellitus |
| Q33691629 | Mesenchymal stem cell therapy in type 2 diabetes mellitus |
| Q35010758 | Metabolic disease puts up a fight: microbes, metabolism and medications |
| Q39084797 | Metabolite Variation in Lean and Obese Streptozotocin (STZ)-Induced Diabetic Rats via 1H NMR-Based Metabolomics Approach. |
| Q35641623 | Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy |
| Q36847318 | Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes |
| Q22241434 | Metformin: new understandings, new uses |
| Q38774878 | Metformin; a review of its history and future: from lilac to longevity |
| Q33983535 | Modulatory Effect of Rice Bran and Phytic Acid on Glucose Metabolism in High Fat-Fed C57BL/6N Mice |
| Q46457054 | Multidisciplinary interventions: mapping new horizons in diabetes care |
| Q34413623 | Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication |
| Q37848045 | Need for better diabetes treatment for improved renal outcome |
| Q47094776 | New Hybrid Hydrazinyl Thiazole Substituted Chromones: As Potential α-Amylase Inhibitors and Radical (DPPH & ABTS) Scavengers |
| Q37004040 | New combination treatments in the management of diabetes: focus on sitagliptin-metformin |
| Q35208539 | New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione |
| Q46865865 | Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention? |
| Q38077451 | Noninsulin glucose-lowering agents for the treatment of patients on dialysis |
| Q36812821 | Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin |
| Q37031367 | Optimizing combination treatment in the management of type 2 diabetes |
| Q22241436 | Oral Antidiabetic Agents |
| Q33713451 | Oral antihyperglycemic therapy for type 2 diabetes mellitus. |
| Q45143740 | Oral diabetes treatment. Which substance is indicated at which time? |
| Q45074004 | Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study |
| Q35916889 | Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study |
| Q34729268 | Patient profiling in diabetes and role of canagliflozin |
| Q37365702 | Personalized pharmacotherapy for Type 2 diabetes mellitus |
| Q35840645 | Pharmacogenetics in type 2 diabetes: potential implications for clinical practice |
| Q36918107 | Pharmacogenetics of thiazolidinedione therapy |
| Q34573733 | Pharmacokinetic interactions with thiazolidinediones |
| Q28252893 | Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects |
| Q91795530 | Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects |
| Q46438885 | Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects |
| Q46220335 | Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus |
| Q43189478 | Physical activity and type 2 diabetes: tailoring exercise to optimize fitness and glycemic control |
| Q86430406 | Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients |
| Q46860919 | Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes |
| Q36570644 | Pioglitazone initiation and subsequent hospitalization for congestive heart failure |
| Q36889127 | Potential roles of erythropoietin in the management of anaemia and other complications diabetes |
| Q80794868 | Pounds off with empowerment (POWER): a clinical trial of weight management strategies for black and white adults with diabetes who live in medically underserved rural communities |
| Q39443326 | Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes |
| Q36652827 | Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus |
| Q33889887 | Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety. |
| Q33628631 | Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin |
| Q43044540 | Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity |
| Q53740973 | Preparation and in vitro/in vivo evaluation of metformin hydrochloride rectal dosage forms for treatment of patients with type II diabetes. |
| Q37732210 | Prescription Patterns and the Cost of Antihyperglycemic Drugs in Patients With Type 2 Diabetes Mellitus in Germany |
| Q38330456 | Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. |
| Q35707809 | Progress with thiazolidinediones in the management of type 2 diabetes mellitus |
| Q39680383 | Protective effect of salidroside from Rhodiolae Radix on diabetes-induced oxidative stress in mice. |
| Q35188027 | Qualitative variation of anti-diabetic compounds in different tarragon (Artemisia dracunculus L.) cytotypes |
| Q37227397 | Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus |
| Q38219491 | Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus |
| Q26798145 | Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update |
| Q37357915 | Red-koji fermented red ginseng ameliorates high fat diet-induced metabolic disorders in mice |
| Q35847886 | Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy. |
| Q62516363 | Regional variation in medication-taking behaviour of new users of oral anti-hyperglycaemic therapy in Ireland |
| Q36843917 | Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). |
| Q34056132 | Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis |
| Q37375217 | Relevance of plasma obestatin and early arteriosclerosis in patients with type 2 diabetes mellitus |
| Q37439364 | Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications |
| Q35118914 | Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression |
| Q41481445 | Results of the Adequacy of glycemiC Control in pAtients with type 2 Diabetes mEllitus treated with Metformin monotherapY at the maximal-tolerated dose (ACCADEMY) study. |
| Q34737169 | Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus |
| Q37724505 | Review article: Diabetes mellitus and heart failure--an overview of epidemiology and management |
| Q38113101 | Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors |
| Q38789093 | Rice bran nutraceutics: A comprehensive review. |
| Q39107791 | Role of Pioglitazone with Metformin or Glimepiride on Oxidative Stress-induced Nuclear Damage and Reproductive Toxicity in Diabetic Rats |
| Q36131766 | Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus |
| Q35906490 | SGLT-2 Inhibitors: A New Mechanism for Glycemic Control |
| Q34117872 | SGLT2 inhibition--a novel strategy for diabetes treatment |
| Q38077305 | SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus |
| Q36763213 | Safety and Efficacy of D-Tagatose in Glycemic Control in Subjects with Type 2 Diabetes |
| Q38380289 | Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis. |
| Q27027877 | Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus |
| Q33562235 | Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes |
| Q42209597 | Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis |
| Q44548336 | Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies |
| Q46350665 | Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers |
| Q35819969 | Salvia libanotica improves glycemia and serum lipid profile in rats fed a high fat diet. |
| Q28278863 | Saxagliptin overview: special focus on safety and adverse effects |
| Q37982112 | Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment |
| Q46548509 | Scutellaria baicalensis enhances the anti-diabetic activity of metformin in streptozotocin-induced diabetic Wistar rats. |
| Q46520634 | Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus |
| Q43137460 | Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes |
| Q36757596 | Sitagliptin |
| Q33633710 | Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes |
| Q37835284 | Sitagliptin and metformin--novel combination therapy |
| Q36792740 | Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects |
| Q46193261 | Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus |
| Q37764285 | Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. |
| Q24313365 | Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2 |
| Q35376455 | Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study |
| Q35783714 | Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride |
| Q30817266 | Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications |
| Q38387199 | TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity |
| Q36973806 | Tagatose, a new antidiabetic and obesity control drug |
| Q33809886 | Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs |
| Q51474535 | Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. |
| Q33946771 | Targeting sirtuins for the treatment of diabetes |
| Q59793451 | The Effect of Small Doses of Fructose and Its Epimers on Glycemic Control: A Systematic Review and Meta-Analysis of Controlled Feeding Trials |
| Q26766298 | The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis |
| Q35778495 | The Informatics for Diabetes and Education Telemedicine (IDEATel) project |
| Q51355945 | The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. |
| Q87286329 | The effect of chairside chronic disease screenings by oral health professionals on health care costs |
| Q37150286 | The effect of duodenojejunal bypass for type 2 diabetes mellitus patients below body mass index 25 kg/m(2): one year follow-up |
| Q51376983 | The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. |
| Q34016145 | The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis |
| Q51475034 | The effects of metformin and glibenclamide on glucose metabolism, counter-regulatory hormones and cardiovascular responses in women with Type 2 diabetes during exercise of moderate intensity. |
| Q37226372 | The effects of pharmacologic agents for type 2 diabetes mellitus on body weight |
| Q84568101 | The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice |
| Q45073994 | The incidence of congestive heart failure associated with antidiabetic therapies |
| Q35659489 | The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial |
| Q38126109 | The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors |
| Q35563453 | The management of the obese diabetic patient |
| Q44659829 | The metabolic syndrome and type 2 diabetes: role of the adipocyte |
| Q37321871 | The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. |
| Q36982574 | The treatment of dyslipidemia--what's left in the pipeline? |
| Q35553698 | The “Glitazones”: Rosiglitazone and Pioglitazone |
| Q37430507 | Thiazolidinediones and bone. |
| Q34628604 | Thiazolidinediones in the treatment of type 2 diabetes |
| Q34121055 | Thiazolidinediones: a 2010 perspective. |
| Q37117876 | Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin |
| Q36141065 | Traffic exposure in a population with high prevalence type 2 diabetes--do medications influence concentrations of C-reactive protein? |
| Q34392292 | Translational potential of a mouse in vitro bioassay in predicting gastrointestinal adverse drug reactions in Phase I clinical trials |
| Q35614289 | Treating diabetes using oral agents |
| Q36283822 | Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. |
| Q36139042 | Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog |
| Q35640959 | Treatment of type 2 diabetes |
| Q36835225 | Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina |
| Q46942534 | Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003. |
| Q41412946 | Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms |
| Q37153041 | Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors |
| Q35279725 | Understanding the rising incidence of type 2 diabetes in adolescence |
| Q37857686 | Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin |
| Q46472449 | Use of oral lipid-lowering drugs in patients with type-2 diabetes mellitus |
| Q33237060 | Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties |
| Q51930185 | Virtual screening for PPAR modulators using a probabilistic neural network. |
| Q47307314 | Weight changes following the initiation of new anti-hyperglycaemic therapies. |
| Q47303510 | Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial |
| Q33654613 | Zanthoxylum alkylamides ameliorate protein metabolism disorder in STZ-induced diabetic rats |
| Q38130502 | Zinc as a potential coadjuvant in therapy for type 2 diabetes. |
| Q80380593 | [Criteria and guidelines for combined therapy of type 2 diabetes. 2004 consensus document] |
| Q81599200 | [New perspectives for the treatment of diabetes mellitus] |
Search more.